Public Employees Retirement System of Ohio Has $11.18 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Public Employees Retirement System of Ohio decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 27,653 shares of the company’s stock after selling 5,875 shares during the period. Public Employees Retirement System of Ohio’s holdings in Medpace were worth $11,176,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI boosted its position in Medpace by 40.3% in the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock valued at $41,000 after buying an additional 29 shares in the last quarter. Miller Howard Investments Inc. NY boosted its position in Medpace by 1.3% in the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after buying an additional 39 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Medpace by 5.3% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after buying an additional 39 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in Medpace by 5.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after buying an additional 45 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Medpace by 43.3% in the first quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock valued at $60,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. TD Cowen dropped their price target on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price target for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Robert W. Baird dropped their price target on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a research note on Wednesday, July 24th. Guggenheim dropped their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Medpace currently has an average rating of “Moderate Buy” and an average price target of $424.14.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction on Friday, May 24th. The shares were sold at an average price of $395.22, for a total value of $1,575,742.14. Following the completion of the sale, the chief executive officer now directly owns 660,351 shares of the company’s stock, valued at $260,983,922.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $395.22, for a total transaction of $1,575,742.14. Following the completion of the transaction, the chief executive officer now directly owns 660,351 shares in the company, valued at $260,983,922.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the transaction, the chief executive officer now owns 654,656 shares of the company’s stock, valued at $258,909,901.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,519 shares of company stock valued at $5,765,631. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP traded up $4.03 during mid-day trading on Monday, reaching $385.50. 236,008 shares of the stock were exchanged, compared to its average volume of 245,422. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The stock has a 50 day simple moving average of $404.32 and a 200-day simple moving average of $383.43. The stock has a market cap of $11.95 billion, a P/E ratio of 38.89, a P/E/G ratio of 1.97 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same quarter last year, the firm earned $1.93 earnings per share. Medpace’s quarterly revenue was up 14.6% on a year-over-year basis. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.69 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.